Briacell Therapeutics Corp

BCT · TO · Healthcare / Biotechnology

4.89CAD-0.01 (-0.20%)

Price History

Full chart

Market Stats

Previous Close4.90

Open4.86

Day Range4.76 – 4.89

52-Week Range3.68 – 20.40

Volume1.85K

Market Cap50.02M

P/E (TTM)0.00

Forward P/E0.00

EPS-1.17

Dividend Yield0.00%

Beta1.53

50-Day Avg5.19

200-Day Avg5.86

About

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. William V. Williams FCPA, M.D.
Employees0
HeadquartersBellevue Centre, West Vancouver, BC, Canada, V7T 2X1, Canada
Websitehttps://briacell.com

Leadership

Dr. William V. Williams FCPA, M.D.CEO, President & Director · b. 1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.CFO & Corporate Secretary · b. 1973
Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer · b. 1970
Dr. Giuseppe Del Priore M.D., M.P.H.Chief Medical Officer · b. 1962
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory Board · b. 1947

Financials

Income Statement

Currency: CAD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31

Currency: CAD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31
Total Revenue	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0
Cost of Revenue	-	-	-	165.79	43.47K	56.13K	72.10K	-79.87K	61.16K	564.63	1.79K	289.88	16.89K	18.73K	18.73K	15.55K	19.39K	20.49K	114.04K	107.93K
Gross Profit	-	-	-	-166	-43.47K	-56.13K	-72.10K	79.87K	-61.16K	-563	-1.79K	-289	-16.89K	-18.73K	-18.73K	-15.55K	-19.39K	-20.49K	-114.04K	-107.93K
Operating Expense	-	-	-	251.29K	290.05K	949.67K	486.28K	368.28K	414.69K	1.87M	2.18M	3.22M	4.96M	6.20M	4.82M	7.10M	15.27M	23.25M	33.22M	27.43M
Operating Income	-8.58K	-137.35K	-116.96K	-251.45K	-333.51K	-1.01M	-558.39K	-288.42K	-475.85K	-1.87M	-2.18M	-3.22M	-4.97M	-6.22M	-4.84M	-7.11M	-15.29M	-23.27M	-33.33M	-27.54M
EBITDA	-8.58K	-137.35K	-116.96K	-251.29K	-332.18K	-1.00M	-556.66K	-288.01K	-474.64K	-1.87M	-2.18M	-3.22M	-4.96M	-6.20M	-4.82M	-7.10M	-26.82M	-23.26M	-4.85M	-27.43M
Net Income	-8.58K	-123.89K	-101.39K	-246.01K	-925.56K	-1.03M	-996.80K	-379.74K	-8.88M	-3.49M	-2.21M	-3.22M	-5.41M	-5.79M	-4.94M	-13.82M	-26.84M	-20.30M	-4.79M	-26.63M
R&D	-	-	-	-	-	-	-	-	-	137.58K	944.91K	2.13M	3.11M	4.92M	2.98M	2.02M	8.02M	15.34M	27.18M	21.53M
Interest Expense	-	-	-	2.73K	2.90K	13.36K	38.01K	16.90K	12.00K	7.09K	3.63K	5.16K	20.35K	31.30K	36.19K	80.09K	979	0	-	37.43K

Balance Sheet

Currency: CAD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31

Currency: CAD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31
Total Assets	96.35K	456.29K	390.29K	1.12M	1.51M	11.78M	10.33M	9.69M	2.82M	1.66M	1.09M	2.04M	2.28M	415.43K	478.31K	58.04M	42.58M	27.16M	5.87M	21.72M
Total Liabilities	16.54K	9.58K	16.03K	69.01K	29.95K	683.69K	284.25K	76.69K	2.00M	152.32K	63.47K	1.10M	1.34M	1.06M	3.77M	30.37M	32.25M	30.94M	8.56M	4.33M
Total Equity	79.82K	446.71K	374.26K	1.05M	1.48M	11.09M	10.05M	9.61M	819.29K	1.51M	1.03M	934.66K	945.02K	-643.49K	-3.29M	27.67M	10.33M	-3.78M	-2.38M	17.94M
Cash	88.40K	445.43K	350.58K	818.94K	1.40M	3.77M	1.50M	995.48K	2.62M	464.43K	171.86K	1.26M	720.26K	146.71K	19.46K	57.27M	41.04M	21.25M	862.09K	10.53M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	2.27M	613.90K	379.88K	25.99K	-	-	-	-
Net Debt	-88.40K	-445.43K	-350.58K	-818.94K	-1.40M	-3.77M	-1.50M	-995.48K	-2.62M	-464.43K	-171.86K	-1.26M	400.40K	154.62K	209.29K	-57.24M	-41.04M	-21.25M	-862.09K	-10.53M

Cash Flow

Currency: USD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31

Currency: USD	2006-07-31	2007-07-31	2008-07-31	2009-07-31	2010-07-31	2011-07-31	2012-07-31	2013-07-31	2014-07-31	2015-07-31	2016-07-31	2017-07-31	2018-07-31	2019-07-31	2020-07-31	2021-07-31	2022-07-31	2023-07-31	2024-07-31	2025-07-31
Operating Cash Flow	-	-93.40K	-87.41K	-151.16K	-317.90K	-658.98K	-381.90K	-379.56K	-396.90K	-1.19M	-1.57M	-1.91M	-4.96M	-5.09M	-1.55M	-7.75M	-12.48M	-23.74M	-24.13M	-28.51M
Investing Cash Flow	-	-	-24.78K	-167.23K	-440.73K	-3.40M	-1.90M	-129.19K	280.41K	-411.09K	207.39K	149.94K	-590.80K	1.34M	0	0	-	-	-681.80K	-7.74M
Financing Cash Flow	88.40K	467.51K	-	778.45K	1.34M	6.42M	24.98K	-	1.74M	2.06M	1.05M	2.90M	5.29M	2.99M	1.44M	65.00M	-3.74M	3.95M	4.42M	46.00M
Capital Expenditure	0	0	0	167.23K	494.95K	2.25M	2.51M	454.99K	157.30K	2.26K	0	4	0	5	0	0	0	0	456.80K	3.1
Free Cash Flow	-	-93.39K	-87.41K	-318.39K	-812.85K	-2.90M	-2.89M	-834.54K	-554.20K	-1.19M	-1.57M	-1.91M	-4.96M	-5.09M	-1.55M	-7.75M	-12.48M	-23.74M	-24.58M	-28.51M
FCF to OCF	-	100.00%	100.00%	210.63%	255.69%	440.74%	757.81%	219.87%	139.63%	100.19%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	101.89%	100.00%

Earnings

Report Date	Mar 14, 2022	Jun 13, 2022	Oct 27, 2022	Dec 14, 2022	Mar 15, 2023	Jun 14, 2023	Oct 25, 2023	Dec 14, 2023	Mar 18, 2024	Jun 14, 2024	Oct 23, 2024	Dec 16, 2024	Mar 12, 2025	Jun 16, 2025	Oct 15, 2025
EPS Estimate	-24.75	-31.50	-0.30	-49.50	-53.25	-53.25	-0.40	-27.00	-30.00	-82.50	-0.64	-12.00	-19.40	-17.60	-12.11
EPS Actual	-36.00	-48.00	-1.02	-10.50	-115.50	-48.00	-0.14	54.00	-106.50	16.50	-0.10	-33.00	-23.30	-16.40	0.04
Surprise	-45.45%	-52.38%	-240.00%	78.79%	-116.90%	9.86%	65.00%	300.00%	-255.00%	120.00%	84.38%	-175.00%	-20.10%	6.82%	100.33%
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours

Key Statistics & Ratios

Market Cap50.02M

Enterprise Value17.93M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book1.48

EPS-1.17

Book Value4.71

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-31.92M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-175.26%

Return on Assets-90.84%

Shares Outstanding8.70M

Shares Float7.86M

Beta1.53

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Aug 25, 20251:10
Jan 29, 20251:15
Sep 5, 20231009:1000
Jan 2, 20201:300
Dec 3, 2014307:1000